Seminars in Oncology
Volume 34, Issue 2 , Pages 145-153 , April 2007

The Atypical Urothelial Cancer Patient: Management of Bladder Cancers of Non–Transitional Cell Histology and Cancers of the Ureters and Renal Pelvis

  • Timothy Gilligan
    • ,
  • Robert Dreicer

      Affiliations

    • Corresponding Author InformationAddress correspondence to Robert Dreicer, MD, FACP, Department of Solid Tumor Oncology, 9500 Euclid Ave R35, Cleveland, OH 44195.

References 

  1. Billis A, Schenka AA, Ramos CC, et al. Squamous and/or glandular differentiation in urothelial carcinoma: Prevalence and significance in transurethral resections of the bladder. Int Urol Nephrol. 2001;33:631–633
  2. El-Sebaie M, Zaghloul MS, Howard G, et al. Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: A review of etiological features, natural history, and management. Int J Clin Oncol. 2005;10:20–25
  3. Lynch CF, Cohen MB. Urinary system. Cancer. 1995;75(suppl 1):316–329
  4. Jozwicki W, Domaniewski J, Skok Z, et al. Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: A mapping study. Urology. 2005;66:1122–1126
  5. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997;80:1966–1972
  6. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050–1055
  7. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol. 1992;10:1066–1073
  8. Ghoneim MA, el-Mekresh MM, el-Baz MA, et al. Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1,026 cases. J Urol. 1997;158:393–399
  9. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: A contemporary series. J Urol. 2001;165:1111–1116
  10. Frazier HA, Robertson JE, Dodge RK, et al. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer. 1993;71:3993–4001
  11. Honma I, Masumori N, Sato E, et al. Local recurrence after radical cystectomy for invasive bladder cancer: An analysis of predictive factors. Urology. 2004;64:744–748
  12. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: A review. Eur Urol. 2003;44:672–681
  13. Boucher NR, Scholefield JH, Anderson JB. The aetiological significance of human papillomavirus in bladder cancer. Br J Urol. 1996;78:866–869
  14. Maloney KE, Wiener JS, Walther PJ. Oncogenic human papillomaviruses are rarely associated with squamous cell carcinoma of the bladder: Evaluation by differential polymerase chain reaction. J Urol. 1994;151:360–364
  15. Westenend PJ, Stoop JA, Hendriks JG. Human papillomaviruses 6/11, 16/18 and 31/33/51 are not associated with squamous cell carcinoma of the urinary bladder. BJU Int. 2001;88:198–201
  16. Bickel A, Culkin DJ, Wheeler JS. Bladder cancer in spinal cord injury patients. J Urol. 1991;146:1240–1242
  17. Melzak J. The incidence of bladder cancer in paraplegia. Paraplegia. 1966;4:85–96
  18. Groah SL, Weitzenkamp DA, Lammertse DP, et al. Excess risk of bladder cancer in spinal cord injury: Evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil. 2002;83:346–351
  19. Subramonian K, Cartwright RA, Harnden P, et al. Bladder cancer in patients with spinal cord injuries. BJU Int. 2004;93:739–743
  20. Pannek J. Transitional cell carcinoma in patients with spinal cord injury: A high risk malignancy?. Urology. 2002;59:240–244
  21. Subramonian K, Harrison SC. Re: Bladder histological changes associated with chronic indwelling urinary catheter. J Urol. 1999;162:2105–2106
  22. Hess MJ, Zhan EH, Foo DK, et al. Bladder cancer in patients with spinal cord injury. J Spinal Cord Med. 2003;26:335–338
  23. Yang CC, Clowers DE. Screening cystoscopy in chronically catheterized spinal cord injury patients. Spinal Cord. 1999;37:204–207
  24. Hamid R, Bycroft J, Arya M, et al. Screening cystoscopy and biopsy in patients with neuropathic bladder and chronic suprapubic indwelling catheters: Is it valid?. J Urol. 2003;170:425–427
  25. West DA, Cummings JM, Longo WE, et al. Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. Urology. 1999;53:292–297
  26. Jones MA, Bloom HJ, Williams G, et al. The management of squamous cell carcinoma of the bladder. Br J Urol. 1980;52:511–514
  27. Tannenbaum SI, Carson CC, Tatum A, et al. Squamous carcinoma of urinary bladder. Urology. 1983;22:597–599
  28. Richie JP, Waisman J, Skinner DG, et al. Squamous carcinoma of the bladder: Treatment by radical cystectomy. J Urol. 1976;115:670–672
  29. Serretta V, Pomara G, Piazza F, et al. Pure squamous cell carcinoma of the bladder in western countries (Report on 19 consecutive cases). Eur Urol. 2000;37:85–89
  30. Rundle JS, Hart AJ, McGeorge A, et al. Squamous cell carcinoma of bladder (A review of 114 patients). Br J Urol. 1982;54:522–526
  31. Navon JD, Soliman H, Khonsari F, et al. Screening cystoscopy and survival of spinal cord injured patients with squamous cell cancer of the bladder. J Urol. 1997;157:2109–2111
  32. Wolchok JD, Herr HW, Kelly WK. Localized squamous cell carcinoma of the bladder causing hypercalcemia and inhibition of PTH secretion. Urology. 1998;51:489–491
  33. Swanson DA, Liles A, Zagars GK. Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J Urol. 1990;143:37–40
  34. Quilty PM, Duncan W. Radiotherapy for squamous carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys. 1986;12:861–865
  35. Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin (ITP) in patients with advanced non–transitional cell (non-TCC) carcinomas of the urothelial tract. Proc Am Soc Clin Oncol. 2006;24:227S;(abstr 4542)
  36. Hassan N, Mounir M, El-Basmi A, et al. Statistical Report for NCI. Volume 2006. Cairo, Egypt: National Cancer Institute; 2001;
  37. Mostafa MH, Sheweita SA, O’Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999;12:97–111
  38. Shokeir AA. Squamous cell carcinoma of the bladder: Pathology, diagnosis and treatment. BJU Int. 2004;93:216–220
  39. Khaled H, El Hattab O, Moneim DA, et al. A prognostic index (bladder prognostic index) for bilharzial-related invasive bladder cancer. Urol Oncol. 2005;23:254–260
  40. Ghoneim MA, Ashamallah AK, Awaad HK, et al. Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol. 1985;134:266–268
  41. Zaghloul MS, Awwad HK, Akoush HH, et al. Postoperative radiotherapy of carcinoma in bilharzial bladder: Improved disease free survival through improving local control. Int J Radiat Oncol Biol Phys. 1992;23:511–517
  42. Khaled H, Zaghloul M, Ghoneim M, et al. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive bladder cancer: Effect on bladder preservation and survival. Proc Am Soc Clin Oncol. 2003;22:411;(abstr 1652)
  43. Zaghloul M, Khaled H, Loutayef M, et al. A phase III randomized controlled trial of adjuvant chemoradiotherapy (CRT) and postoperative radiotherapy (PORT) versus PORT alone in high risk bladder cancer patients. Proc Am Soc Clin Oncol. 2005;23:398S;(abstr 4584)
  44. Zaghloul MS. Distant metastasis from bilharzial bladder cancer. Cancer. 1996;77:743–749
  45. Khaled HM, Hamza MR, Mansour O, et al. A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma. Eur J Cancer. 2000;36(suppl 2):34–37
  46. Khaled HM, Gad el-Mawla N, el-Said A, et al. Combination chemotherapy for advanced bilharzial bladder carcinoma. Ann Oncol. 1996;7:751–754
  47. Gad-el-Mawla N, Hamza MR, Zikri ZK, et al. Chemotherapy in invasive carcinoma of the bladder (A review of phase II trials in Egypt). Acta Oncol. 1989;28:73–76
  48. Zaghloul MS, Nouh A, Nazmy M, et al. Long-term results of primary adenocarcinoma of the urinary bladder: A report on 192 patients. Urol Oncol. 2006;24:13–20
  49. el-Mekresh MM, el-Baz MA, Abol-Enein H, et al. Primary adenocarcinoma of the urinary bladder: A report of 185 cases. Br J Urol. 1998;82:206–212
  50. Wilson TG, Pritchett TR, Lieskovsky G, et al. Primary adenocarcinoma of bladder. Urology. 1991;38:223–226
  51. Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: Clinicopathological and histological features of 282 cases. Histopathology. 2000;36:32–40
  52. Filmer RB, Spencer JR. Malignancies in bladder augmentations and intestinal conduits. J Urol. 1990;143:671–678
  53. Shokeir AA, Shamaa M, el-Mekresh MM, et al. Late malignancy in bowel segments exposed to urine without fecal stream. Urology. 1995;46:657–661
  54. Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol. 2001;25:1380–1387
  55. Bardales RH, Pitman MB, Stanley MW, et al. Urine cytology of primary and secondary urinary bladder adenocarcinoma. Cancer. 1998;84:335–343
  56. Edgerton ME, Hoda RS, Gupta PK. Cytologic diagnosis of metastatic ovarian adenocarcinoma in the urinary bladder: A case report and review of the literature. Diagn Cytopathol. 1999;20:156–159
  57. Nakanishi K, Tominaga S, Kawai T, et al. Mucin histochemistry in primary adenocarcinoma of the urinary bladder (of urachal or vesicular origin) and metastatic adenocarcinoma originating in the colorectum. Pathol Int. 2000;50:297–303
  58. Pantuck AJ, Murphy DP, Amenta PS, et al. The monoclonal antibody 7E12H12 can differentiate primary adenocarcinoma of the bladder and prostate. Br J Urol. 1998;82:426–430
  59. Paulhac P, Maisonnette F, Bourg S, et al. Adenocarcinoma in the exstrophic bladder. Urology. 1999;54:744
  60. Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder (A clinicopathologic analysis of 72 cases). Cancer. 1991;67:2165–2172
  61. Dandekar NP, Dalal AV, Tongaonkar HB, et al. Adenocarcinoma of bladder. Eur J Surg Oncol. 1997;23:157–160
  62. Siefker-Radtke AO, Gee J, Shen Y, et al. Multimodality management of urachal carcinoma: The M.D. Anderson Cancer Center experience. J Urol. 2003;169:1295–1298
  63. Cothren C, Ferucci P, Harken AH, et al. Urachal carcinoma: Key points for the general surgeon. Am Surg. 2002;68:201–203
  64. Herr HW. Urachal carcinoma: The case for extended partial cystectomy. J Urol. 1994;151:365–366
  65. Henly DR, Farrow GM, Zincke H. Urachal cancer: Role of conservative surgery. Urology. 1993;42:635–639
  66. Quek ML, Nichols PW, Yamzon J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: The University of Southern California experience. J Urol. 2005;174:93–96
  67. Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder (The Mayo Clinic experience). Cancer. 2005;103:1172–1178
  68. Bex A, Nieuwenhuijzen JA, Kerst M, et al. Small cell carcinoma of bladder: A single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology. 2005;65:295–299
  69. Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: A retrospective review of the M.D. Anderson cancer experience. J Urol. 2004;172:481–484
  70. Mangar SA, Logue JP, Shanks JH, et al. Small-cell carcinoma of the urinary bladder: 10-year experience. Clin Oncol (R Coll Radiol). 2004;16:523–527
  71. Cheng L, Pan CX, Yang XJ, et al. Small cell carcinoma of the urinary bladder: A clinicopathologic analysis of 64 patients. Cancer. 2004;101:957–962
  72. Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005;166:1533–1539
  73. Lohrisch C, Murray N, Pickles T, et al. Small cell carcinoma of the bladder: Long term outcome with integrated chemoradiation. Cancer. 1999;86:2346–2352
  74. Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol. 2003;47:155–169
  75. Cohen RA, Brown RS. Clinical practice (Microscopic hematuria). N Engl J Med. 2003;348:2330–2338
  76. Tolley DA, Esposito MP. Laparoscopic and renal sparing approaches to tumours of the ureter and kidney. Surg Oncol. 2002;11:47–54
  77. McNeill A, Oakley N, Tolley DA, et al. Laparoscopic nephroureterectomy for upper tract transitional cell carcinoma: A critical appraisal. BJU Int. 2004;94:259–263
  78. Johnson GB, Grasso M. Ureteroscopic management of upper urinary tract transitional cell carcinoma. Curr Opin Urol. 2005;15:89–93
  79. Daneshmand S, Quek ML, Huffman JL. Endoscopic management of upper urinary tract transitional cell carcinoma: Long-term experience. Cancer. 2003;98:55–60
  80. Lee BR, Jabbour ME, Marshall FF, et al. 13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: Equivalent outcomes. J Endourol. 1999;13:289–294
  81. Elliott DS, Segura JW, Lightner D, et al. Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? (Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney). Urology. 2001;58:174–178
  82. Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: Long-term followup. J Urol. 2003;169:925–929
  83. Jabbour ME, Smith AD. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am. 2000;27:739–750
  84. Thalmann GN, Markwalder R, Walter B, et al. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol. 2002;168:1381–1385
  85. Irie A, Iwamura M, Kadowaki K, et al. Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology. 2002;59:53–57
  86. Bassi P, Iafrate M, Longo F, et al. Intracavitary therapy of noninvasive transitional cell carcinomas of the upper urinary tract (A review of the literature). Urol Int. 2001;67:189–194
  87. Nonomura N, Ono Y, Nozawa M, et al. Bacillus Calmette-Guerin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol. 2000;38:701–704
  88. Oehlschlager S, Baldauf A, Wiessner D, et al. Bladder tumor recurrence after primary surgery for transitional cell carcinoma of the upper urinary tract. Urol Int. 2004;73:209–211
  89. Chen GL, Bagley DH. Ureteroscopic surgery for upper tract transitional-cell carcinoma: Complications and management. J Endourol. 2001;15:399–404
  90. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866
  91. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. Journal of Clinical Oncology. 1999;17:3173–3181
  92. Bamias A, Deliveliotis C, Fountzilas G, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: A study by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:2150–2154
  93. Vaughn DJ, Manola J, Dreicer R, et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): A trial of the Eastern Cooperative Oncology Group. Cancer. 2002;95:1022–1027
  94. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100:1639–1645

PII: S0093-7754(06)00482-9

doi: 10.1053/j.seminoncol.2006.12.005

Seminars in Oncology
Volume 34, Issue 2 , Pages 145-153 , April 2007

Article Tools